Economic Assessment of Home-Based COPD Management Programs

References

• Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(2 Suppl):5S–9S.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health National Heart Lung and Blo-od Institute Morbidity & Mortality: Chart Book on Cardio-vascular, Lung, and Blood Diseases. 2009 [cited 2013 March 1, 2013]; Available from: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.
   Google Scholar
• Simoens S. The economic burden of COPD exacerbations. COPD, 2010; 7(3):159–61.
   PubMedGoogle Scholar
• Andersson F, The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9):700–8.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1):1418–22.
   PubMed Web of Science ®Google Scholar
• Menn PN, Weber, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010; 8:39.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010. 363(12): p. 1128–38.
   PubMed Web of Science ®Google Scholar
• Bourbeau J. Disease management for COPD: avoiding hospitalizations and controlling cost? COPD 2011; 8(3):143–144.
   PubMedGoogle Scholar
• Newhouse JP. Financing Medicare in the next administration. N Engl J Med 2004; 351(17):1714–6.
   PubMed Web of Science ®Google Scholar
• Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med 2005; 353(14): 1516–22.
   PubMed Web of Science ®Google Scholar
• Warren PM, Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961–68 and 1970–76. Lancet 1980; 1(8166):467–70.
   PubMed Web of Science ®Google Scholar
• Connors AF Jr, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med, 1996; 154(4 Pt 1):959–67.
   PubMed Web of Science ®Google Scholar
• Hoogendoorn M, Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010; 5:435–44.
   PubMedGoogle Scholar
• Halpin DM. Health economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2006; 3(3): 227–33.
   PubMedGoogle Scholar
• Rutten-van Molken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 2006; 3(7):630–4.
   PubMedGoogle Scholar
• Seemungal TA, Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2000; 161(5):1608–13.
   PubMed Web of Science ®Google Scholar
• Fuso L, Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med, 1995; 98(3):272–7.
   PubMed Web of Science ®Google Scholar
• Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One 2011; 6(9):e24870.
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Probabilistic markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value in Health 2005; 8(1): 32–46.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010; 5:341–9.
   PubMedGoogle Scholar
• Yu AP, Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011; 14(3):315–23.
   PubMedGoogle Scholar
• Borg S, A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health, 2004; 7(2):153–67.
   PubMed Web of Science ®Google Scholar
• Mittmann N, The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med, 2008; 102(3):413–21.
   PubMed Web of Science ®Google Scholar
• Paterson C, Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9(5):521–7.
   PubMed Web of Science ®Google Scholar
• Dalal AA, Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011; 105(3):454–60.
   PubMed Web of Science ®Google Scholar
• Stanford RH, Shen Y, McLaughlin T. Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US Hospitals. Treat Respir Med, 2006; 5(5):343–9.
   PubMedGoogle Scholar
• Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax, 2003; 58(7):589–93.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. [cited 2011; Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp.
   Google Scholar
• Siegel J, Guidelines for Pharmacoeconomic Studies. PharmacoEconomics, 1997; 11(2):159–168.
   PubMed Web of Science ®Google Scholar
• Lewis KE, Home telemonitoring and quality of life in stable, optimised chronic obstructive pulmonary disease. J Telemed Telecare, 2010; 16(5):253–9.
   PubMed Web of Science ®Google Scholar
• Lewis KE, Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD, 2010; 7(1):44–50.
   PubMedGoogle Scholar
• Hanna B. Evaluation Report for COPD Telehealth Project. 2008.
   Google Scholar
• McLean S, Telehealthcare for chronic obstructive pulmonary disease: Cochrane Review and meta-analysis. Br J Gen Pract. 62(604):e739–49.
   PubMed Web of Science ®Google Scholar
• Mapel DW, A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 28(9): 733–49.
   PubMed Web of Science ®Google Scholar
• Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy. 9(5):331–47.
   PubMedGoogle Scholar
• Girling, AJ, Lilford RJ, Young TP. Pricing of medical devices under coverage uncertainty-a modelling approach. Health Econ. 21(12):1502–7.
   PubMed Web of Science ®Google Scholar
• Ginsburg ME. Cost-effectiveness: will the public buy it or balk? Health Aff (Millwood), 2004. Suppl Web Exclusives: p. W4-297–9.
   Google Scholar
• Bloom BS. Use of formal benefit/cost evaluations in health system decision making. Am J Manag Care, 2004; 10(5): 329–35.
   PubMed Web of Science ®Google Scholar
• Statement for Ways and Means hearing to examine comparative effectiveness. 2007 [cited 2011; Available from: www.bcbs.com/news/bcbsa/statement-on-ways-and-means-hearing-to-examine-comparative-effectiveness-research.html.
   Google Scholar
• Vallejo-Torres L, Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus. Med Decis Making, 2011; 31(4): 596–610.
   PubMed Web of Science ®Google Scholar
• Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy, 2011; 9(5):331–47.
   PubMedGoogle Scholar